Form 8-K - Current report:
SEC Accession No. 0001193125-21-105588
Filing Date
2021-04-05
Accepted
2021-04-05 07:07:30
Documents
14
Period of Report
2021-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d163897d8k.htm   iXBRL 8-K 41660
2 EX-5.1 d163897dex51.htm EX-5.1 9487
6 GRAPHIC g163897g0402150410642.jpg GRAPHIC 2534
  Complete submission text file 0001193125-21-105588.txt   185567

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20210331.xsd EX-101.SCH 3050
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20210331_lab.xml EX-101.LAB 18137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20210331_pre.xml EX-101.PRE 11394
7 EXTRACTED XBRL INSTANCE DOCUMENT d163897d8k_htm.xml XML 3363
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 21803714
SIC: 2836 Biological Products, (No Diagnostic Substances)